Allergic Rhinitis in Children and Adolescents

2021 ◽  
Vol 41 (4) ◽  
pp. 613-625
Author(s):  
Charles Frank Schuler IV ◽  
Jenny Maribel Montejo
2010 ◽  
Vol 0 (0) ◽  
Author(s):  
Silvia M. A. Campanha ◽  
Maria J. F. Fontes ◽  
Paulo A. M. Camargos ◽  
Lincoln M. S. Freire (in memorian)

Author(s):  
Ricardo J. Saranz ◽  
Natalia A. Lozano ◽  
Alejandro Lozano ◽  
Graciela Alegre ◽  
Paula Robredo ◽  
...  

2019 ◽  
Vol 66 (5) ◽  
pp. 981-993 ◽  
Author(s):  
Charles Frank Schuler IV ◽  
Jenny Maribel Montejo

2018 ◽  
Vol 6 (5) ◽  
pp. 1752-1755.e3 ◽  
Author(s):  
Franklin Mariño-Sanchez ◽  
Meritxell Valls-Mateus ◽  
Oliver Haag ◽  
Isam Alobid ◽  
Jean Bousquet ◽  
...  

2015 ◽  
Vol 135 (2) ◽  
pp. AB270 ◽  
Author(s):  
Seo Hee Yoon ◽  
Yoon Hee Kim ◽  
Young A. Park ◽  
In Suk Sol ◽  
Min Jung Kim ◽  
...  

2012 ◽  
Vol 47 (11) ◽  
pp. 1070-1079 ◽  
Author(s):  
Jirina Chládková ◽  
Marian Senkerík ◽  
Zuzana Havlínová ◽  
Irena Krcmová ◽  
Jaroslav Chládek

Immunotherapy ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 227-239
Author(s):  
Li Xiang ◽  
Fengxia Liu ◽  
Lili Zhi ◽  
Weihong Jiang ◽  
Changshan Liu ◽  
...  

Aim: Multicenter study to investigate the safety of mite extract product Novo-Helisen Depot, Strengths 1 to 3 (NHD3), as subcutaneous immunotherapy (SCIT), in Chinese children and adolescents with allergic rhinitis (AR) and allergic asthma (AA). Patients & methods: We evaluated SCIT-related adverse events (AEs) during NHD3 14-week initial therapy in children (5–11 years) and adolescents (12–17 years) with perennial symptomatic AR and AA. Results: Among 3600 injections in 250 patients, 361/3600 (10.0%) injections caused SCIT-related AEs in 96/250 (38.4%) patients, 321/3600 injections (8.9%) caused local reactions in 89/250 (35.6%) and 40/3600 injections (1.1%) caused systemic reactions in 23/250 (9.2%). Conclusion: Initial SCIT treatment using NHD3 was safe and well tolerated in Chinese children and adolescents with AR and AA.


Sign in / Sign up

Export Citation Format

Share Document